CD40-gp39 INTERACTIONS PLAY A CRITICAL ROLE DURING ALLOGRAFT REJECTION
Christian P. Larsen(Emory University Hospital), Thomas C. Pearson(Emory Healthcare), Rose Hendrix(Emory Healthcare), Eric T. Elwood(Emory University), Alejandro Aruffo(University of Washington Medical Center), Shannon C. Ritchie(Emory University), Diane Z. Alexander(Emory University), Diane Hollenbaugh(Neoleukin Therapeutics (United States))
Cited by 326
Related Papers
Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways
|Nature|1996|1.5k
The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome
|Cell|1993|824
4-1BB Costimulatory Signals Preferentially Induce CD8+ T Cell Proliferation and Lead to the Amplification In Vivo of Cytotoxic T Cell Responses
|The Journal of Experimental Medicine|1997|802
Rational Development of LEA29Y (belatacept), a High-Affinity Variant of CTLA4-Ig with Potent Immunosuppressive Properties
|American Journal of Transplantation|2005|714
IMMUNE REGULATION BY CD40 AND ITS LIGAND GP39
|Annual Review of Immunology|1996|640